November 18, 2011

Timing of Basiliximab Induction and Development of Acute Rejection in Lung Transplant Patients


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Basiliximab is a monoclonal interleukin-2 receptor antagonist commonly used for induction immunosuppression in lung transplantation.  This single centre retrospective review of 119 patients transplanted between 1994 and 2009 examined the impact of the timing of basiliximab dosing on the frequency and severity of acute rejection, the development of BOS, and overall survival.  Pre-implantation administration of basiliximab was associated with lower cumulative acute rejection scores over one year compared to post-implantation dosing, but there was no significant difference in freedom from BOS or survival.

Lung Transplantation

Tags: , , , , , ,